Question 1

What is Lyell Immunopharma?

Accepted Answer

Lyell Immunopharma is a Company.

Question 2

How often does Lyell Immunopharma appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 12 articles.

Question 3

When was Lyell Immunopharma first tracked by Ergen?

Accepted Answer

First tracked on Apr 20, 2026.

Question 4

When was Lyell Immunopharma last mentioned in news?

Accepted Answer

Last active on Jul 06, 2026.

Question 5

What is Lyell Immunopharma's current news sentiment?

Accepted Answer

Aggregate sentiment score: 32 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Lyell Immunopharma in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Lyell Immunopharma?

Accepted Answer

Lyell Immunopharma LYL273 Trial Update (Jun 08, 2026, 6 articles).

Question 8

How did the "Lyell Immunopharma LYL273 Trial Update" event impact Lyell Immunopharma?

Accepted Answer

Lyell Immunopharma provided an update on the safety profile of LYL273 and amended its Phase 1 trial to a Phase 1/2 design, which could accelerate the development of its CAR T-cell therapy for metastatic colorectal cancer.

Question 9

How did the "AbCellera Appoints Lynn Seely to Board" event impact Lyell Immunopharma?

Accepted Answer

Dr. Lynn Seely currently serves as president and CEO of Lyell Immunopharma Inc., which highlights her current leadership role outside of AbCellera.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.